Develops drugs for retinal diseases like macular degeneration.
Jun 2026Revenue $2.79M/yrExpenses $320M/yr
No trendCash runway ≈ 8 months from Jun 2026
Figures by year
When will EyePoint be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $2.79M and expenses $320M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $31.4M | $275M | −$243M |
| Dec 2024 | $43.3M | $189M | −$146M |
| Dec 2023 | $46.0M | $121M | −$75.1M |
| Dec 2022 | $41.4M | $141M | −$99.6M |
| Dec 2021 | $36.9M | $92.2M | −$55.3M |
| Dec 2020 | $34.4M | $71.7M | −$37.3M |
| Dec 2019 | $20.4M | $68.2M | −$47.9M |
| Dec 2018 | $4.57M | $43.6M | −$39.0M |
| Jun 2018 | $2.96M | $29.2M | −$26.3M |
| Jun 2017 | $7.54M | $26.1M | −$18.6M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.